Prevention & lipidsRandomised controlled trial
Zodasiran, an RNA Interference (RNAi) Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia
- Randomised controlled trial
- double-blind
- placebo-controlled
- dose-ranging
- phase 2b
Authors' conclusion
In patients with mixed hyperlipidemia, zodasiran was associated with significant decreases in triglyceride levels at 24 weeks.
Study context
- Population
- Adults with mixed hyperlipidemia (fasting TG 150–499 mg/dL and LDL-C ≥70 mg/dL or non-HDL cholesterol ≥100 mg/dL)
- Participants
- 204 adults
- Comparison
- Zodasiran vs placebo
- Primary endpoint
- Percent change in TG level from baseline
- Follow-up
- Week 24
Primary result
As reported in the abstract
Percent change in TG
- Zodasiran 50 mg
- difference in change −51 percentage points; P < 0.001
- Zodasiran 100 mg
- difference in change −57 percentage points; P < 0.001
- Zodasiran 200 mg
- difference in change −63 percentage points; P < 0.001
Further findings
| Outcome | difference in change (percentage points) | P value |
|---|---|---|
| ANGPTL3 level, % change · week 24 — Zodasiran 50 mg vs Placebo | −54 | P < 0.001 |
| ANGPTL3 level, % change · week 24 — Zodasiran 100 mg vs Placebo | −70 | P < 0.001 |
| ANGPTL3 level, % change · week 24 — Zodasiran 200 mg vs Placebo | −74 | P < 0.001 |
| Non-HDL cholesterol, % change — Zodasiran 50 mg vs Placebo | −29 | |
| Non-HDL cholesterol, % change — Zodasiran 100 mg vs Placebo | −29 | |
| Non-HDL cholesterol, % change — Zodasiran 200 mg vs Placebo | −36 | |
| Apolipoprotein B, % change — Zodasiran 50 mg vs Placebo | −19 | |
| Apolipoprotein B, % change — Zodasiran 100 mg vs Placebo | −15 | |
| Apolipoprotein B, % change — Zodasiran 200 mg vs Placebo | −22 | |
| LDL-C, % change — Zodasiran 50 mg vs Placebo | −16 | |
| LDL-C, % change — Zodasiran 100 mg vs Placebo | −14 | |
| LDL-C, % change — Zodasiran 200 mg vs Placebo | −20 |
Original publication
Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia. N Engl J Med. Published 29 May 2024. doi:10.1056/nejmoa2404147
Summarised from the published abstract; every number is checked against it